Postoperative adjuvant sorafenib improves survival outcomes in hepatocellular carcinoma patients with microvascular invasion after R0 liver resection: a propensity score matching analysis
文献类型：期刊论文
| 作者 | Zhang, Xiu-Ping6; Chai, Zong-Tao6; Chen, Zhen-Hua6; Wang, Kang6; Shi, Jie6; Guo, Wei-Xing6; Lau, Wan Y.6; Cheng, Shu-Qun6; Gao, Yu-Zhen5; Zhou, Teng-Fei4 |
| 刊名 | HPB
 |
| 出版日期 | 2019 |
| 卷号 | 21期号:12页码:1687-1696 |
| 关键词 | VLDLR PPAR FGF21 ATF4 ER stress |
| ISSN号 | 1365-182X |
| DOI | 10.1016/j.hpb.2019.04.014 |
| 文献子类 | Article |
| 英文摘要 | Background: Microvascular invasion (MVI) is a major determinant of survival outcome for hepatocellular carcinoma (HCC). This study aimed to investigate the efficacy of postoperative adjuvant Sorafenib (PA-Sorafenib) in HCC patients with MVI after R0 liver resection (LR). Methods: The data of patients who underwent R0 LR for HCC with histologically confirmed MVI at the Eastern Hepatobiliary Surgery Hospital were retrospectively analyzed. The survival outcomes for patients who underwent PA-Sorafenib were compared with those who underwent R0 LR alone. Propensity score matching (PSM) analysis was performed. Results: 728 HCC patients had MVI in the resected specimens after R0 resection, with 581 who underwent LR alone and 147 patients who received in additional adjuvant sorafenib. PSM matched 113 patients in each of these two groups. The overall survival (OS) and recurrence free survival (RFS) were significantly better for patients in the PA-sorafenib group (for OS: before PSM, P = 0.003; after PSM, P = 0.007), (for RFS: before PSM, P = 0.029; after PSM, P = 0.001), respectively. Similar results were obtained in patients with BCLC 0-A, BCLC B and Child-Pugh A stages of disease. Conclusions: PA-Sorafenib was associated with significantly better survival outcomes than LR alone for HCC patients with MVI. |
| 学科主题 | Biochemistry & Molecular Biology ; Genetics & Heredity |
| WOS关键词 | TRANSCATHETER ARTERIAL CHEMOEMBOLIZATION ; CLINICAL-PRACTICE GUIDELINES ; EFFICACY ; CANCER ; TRANSPLANTATION ; RECURRENCE ; SAFETY ; HEPATECTOMY ; COMBINATION ; ABLATION |
| 语种 | 英语 |
| CSCD记录号 | CSCD:31153833 |
| WOS记录号 | WOS:000500283700011 |
| 出版者 | ELSEVIER SCI LTD |
| 版本 | 出版稿 |
| 源URL | [http://202.127.25.144/handle/331004/823]  |
| 专题 | 中国科学院上海生命科学研究院营养科学研究所 |
| 作者单位 | 1.Chinese Univ Hong Kong, Fac Med, Shatin, Hong Kong, Peoples R China, 2.Chinese Acad Sci, Shanghai Inst Biol Sci, Key Lab Nutr Metab & Food Safety, 320 Yueyang Rd, Shanghai 200031, Peoples R China; 3.Second Mil Med Univ, Eastern Hepatobiliary Surg Hosp, Dept Pathol, Shanghai, Peoples R China; 4.Second Mil Med Univ, Eastern Hepatobiliary Surg Hosp Inst, Int Cooperat Lab Signal Transduct, Shanghai, Peoples R China; 5.Yangzhou Univ, Clin Med Coll, Dept Mol Diag, Yangzhou, Jiangsu, Peoples R China; 6.Second Mil Med Univ, Eastern Hepatobiliary Surg Hosp, Dept Hepat Surg 6, Shanghai, Peoples R China; |
| 推荐引用方式 GB/T 7714 | Zhang, Xiu-Ping,Chai, Zong-Tao,Chen, Zhen-Hua,et al. Postoperative adjuvant sorafenib improves survival outcomes in hepatocellular carcinoma patients with microvascular invasion after R0 liver resection: a propensity score matching analysis[J]. HPB,2019,21(12):1687-1696. |
| APA | Zhang, Xiu-Ping.,Chai, Zong-Tao.,Chen, Zhen-Hua.,Wang, Kang.,Shi, Jie.,...&,.(2019).Postoperative adjuvant sorafenib improves survival outcomes in hepatocellular carcinoma patients with microvascular invasion after R0 liver resection: a propensity score matching analysis.HPB,21(12),1687-1696. |
| MLA | Zhang, Xiu-Ping,et al."Postoperative adjuvant sorafenib improves survival outcomes in hepatocellular carcinoma patients with microvascular invasion after R0 liver resection: a propensity score matching analysis".HPB 21.12(2019):1687-1696. |
入库方式： OAI收割
来源：上海营养与健康研究所
浏览0
下载0
收藏0
其他版本
除非特别说明，本系统中所有内容都受版权保护，并保留所有权利。